The Bombay High Court has permanently stopped RB Remedies Pvt. Ltd. and Origin Formulations Pvt. Ltd. from making or selling cough syrup under the name 'CEFDON'. The court said this name is confusingly similar to 'CEDON', a brand owned by Blue Cross Laboratories. The order came from Justice Arif S. Doctor on December 16. The dispute began in 2014 when Blue Cross noticed RB Remedies selling syrup called 'CEFDON'. Blue Cross has used 'CEDON' since 2004 and its trademark dates back to 1996. Blue Cross sent a cease-and-desist notice in August 2014, but RB Remedies kept using the name. Advocate Vinod Bhagat, representing Blue Cross, said, "The defendants’ use of the impugned mark ‘CEFDON’ is clearly mala fide and dishonest. They are attempting to encash on goodwill and reputation." He also pointed out the entire trademark 'CEDON' is inside 'CEFDON' and cited a Supreme Court case that looks at overall similarity, including sound. The defendants did not appear or fight the case. Reviewing sales data, the court found RB Remedies’ sales rose from ₹13.93 crore in 2014-15 to ₹25.65 crore in 2024-25, showing growth under the disputed mark. Justice Doctor said, "There can be no manner of doubt that the registered trademark ‘CEDON’ has been entirely subsumed in the impugned mark ‘CEFDON’. Equally, there can be no doubt that there is both visual and phonetic similarity. The likelihood of confusion and deception is evident." The court added, "This likelihood of confusion and the evident deception are more than likely to cause consumers to purchase the defendant’s product and thereby cause loss to the plaintiff." The judge called the use of 'CEFDON' "entirely dishonest and actuated by bad faith" and saw no evidence of honest use. To punish and deter such conduct, the court asked both companies to pay ₹5 lakh each, totaling ₹10 lakh, as costs within 8 weeks. If they fail, interest at 8% per annum will apply. The court noted the importance of public health and safety because the products are pharmaceutical. This stricter cost award follows rules under the Commercial Courts Act. The final order was published on December 19, 2025.